Literature DB >> 11226426

Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor.

Q Chen1, H Kaji, T Sugimoto, K Chihara.   

Abstract

Androgens play an important role in the regulation of bone metabolism in animals and humans. The present study was performed to investigate whether androgens would affect osteoclast formation stimulated by parathyroid hormone (PTH) in mouse bone cell cultures and its mechanism. Testosterone as well as alpha-dihydrotestosterone (DHT) concentration-dependently inhibited osteoclast formation induced by PTH-(1-34). 10(-8) M ICI 182780, an estrogen receptor inhibitor, did not affect PTH-induced osteoclast formation antagonized by 10(-8) M testosterone, although it completely antagonized the effects of 10(-8) M 17beta-estradiol. Moreover, 3 microM 4-androsten-4-ol-3,17-dione, an aromatase inhibitor, did not affect PTH-induced osteoclast formation antagonized by testosterone. Hydroxyflutamide, an androgen receptor antagonist, concentration-dependently antagonized the inhibitory effects of testosterone as well as DHT on PTH-stimulated osteoclast formation. In conclusion, the present study first demonstrated that testosterone inhibited osteoclast formation stimulated by PTH through the androgen receptor, but not through the production of intrinsic estrogen in mouse bone cell cultures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226426     DOI: 10.1016/s0014-5793(01)02160-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Effect on bone mineral density in surgical versus medical castration for metastatic prostate cancer.

Authors:  Mohamed Sharafeldeen; Mohamed Elsaqa; Wael Sameh; Ahmed Elabbady
Journal:  Turk J Urol       Date:  2021-03-01

2.  Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton.

Authors:  Kristine M Wiren; Anthony A Semirale; Xiao-Wei Zhang; Adrian Woo; Steven M Tommasini; Christopher Price; Mitchell B Schaffler; Karl J Jepsen
Journal:  Bone       Date:  2008-05-16       Impact factor: 4.398

3.  Pathogenesis of Osteoporosis.

Authors:  Sundeep Khosla
Journal:  Transl Endocrinol Metab       Date:  2010-04

4.  Androgen receptors and experimental bone loss - an in vivo and in vitro study.

Authors:  Joao Paulo Steffens; Leila Santana Coimbra; Carlos Rossa; Alpdogan Kantarci; Thomas E Van Dyke; Luis Carlos Spolidorio
Journal:  Bone       Date:  2015-10-09       Impact factor: 4.398

Review 5.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

Review 6.  Androgen deficiency in the aging male: pathophysiology, diagnosis, and treatment alternatives.

Authors:  V Flynn; W J Hellstrom
Journal:  Curr Urol Rep       Date:  2001-12       Impact factor: 2.862

Review 7.  Human androgen deficiency: insights gained from androgen receptor knockout mouse models.

Authors:  Kesha Rana; Rachel A Davey; Jeffrey D Zajac
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285

Review 8.  Safety and efficacy of testosterone gel in the treatment of male hypogonadism.

Authors:  Kishore M Lakshman; Shehzad Basaria
Journal:  Clin Interv Aging       Date:  2009-11-18       Impact factor: 4.458

9.  Sex steroids and bone health status in men.

Authors:  Kok-Yong Chin; Soelaiman Ima-Nirwana
Journal:  Int J Endocrinol       Date:  2012-10-24       Impact factor: 3.257

10.  Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone.

Authors:  Yan-Jiao Wang; Jun-Kun Zhan; Wu Huang; Yi Wang; Yuan Liu; Sha Wang; Pan Tan; Zhi-Yong Tang; You-Shuo Liu
Journal:  Int J Endocrinol       Date:  2013-03-04       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.